MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.330
+0.230
+5.61%
Pre Market: 4.270 -0.06 -1.39% 04:26 06/17 EDT
OPEN
4.230
PREV CLOSE
4.100
HIGH
4.580
LOW
4.195
VOLUME
251
TURNOVER
--
52 WEEK HIGH
6.25
52 WEEK LOW
1.520
MARKET CAP
1.08B
P/E (TTM)
-16.1567
1D
5D
1M
3M
1Y
5Y
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA
/PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Appli...
PR Newswire - PRF · 17h ago
MannKind Shares Rise 9% After Priority Review for Tyvaso DPI NDA
marketwatch.com · 17h ago
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.
PR Newswire - PRF · 20h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 20h ago
MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension
Benzinga · 21h ago
FDA grants accelerated review to United Therapeutics' Tyvaso DPI application
Under priority review, the FDA has accepted United Therapeutics' (UTHR) New Drug Application ((NDA)) for Tyvaso DPI (inhaled treprostinil) for the treatment of pulmonary arterial hypertension ((PAH)) and pulmonary hypertension
Seekingalpha · 22h ago
BRIEF-United Therapeutics Announces FDA Acceptance Of Tyvaso Dpi™ New Drug Application For Priority Review
reuters.com · 22h ago
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
Tyvaso DPI includes the second compound formulated with MannKind’s Technosphere® technology to be reviewed by the FDAFDA review expected to be complete in October 2021Hiring expansion underway at MannKind’s manufacturing facility in Connecticut DANBURY, Co...
GlobeNewswire · 22h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNKD. Analyze the recent business situations of MannKind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNKD stock price target is 6.17 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 226
Institutional Holdings: 112.75M
% Owned: 45.25%
Shares Outstanding: 249.16M
TypeInstitutionsShares
Increased
59
31.58M
New
29
3.51M
Decreased
33
2.31M
Sold Out
17
1.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.64%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
James Shannon
Chief Executive Officer/Director
Michael Castagna
Chief Financial Officer
Steven Binder
Chief Human Resource Officer
Stuart Tross
Executive Vice President/General Counsel/Secretary
David Thomson
Chief Technology Officer
Joseph Kocinsky
Independent Director
Ronald Consiglio
Other
Patrick McCauley
Independent Director
Michael Friedman
Independent Director
Jennifer Grancio
Independent Director
Anthony Hooper
Independent Director
Sabrina Kay
Independent Director
Kent Kresa
Independent Director
Christine Mundkur
Independent Director
David Maccallum
No Data
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company's product candidate is Afrezza (insulin human) Inhalation Powder, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its technosphere formulation technology. The technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics.

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.